White Rose University Consortium logo
University of Leeds logo University of Sheffield logo York University logo

The MS Symptom and Impact Diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis

Greenhalgh, J, Ford, H, Long, AF and Hurst, K (2004) The MS Symptom and Impact Diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 75 (4). pp. 577-582. ISSN 0022-3050

Full text available as:
[img]
Preview
Text
hurstk1.pdf
Available under licence : See the attached licence file.

Download (234Kb)
Published Version: http://www.jnnp.com/

Abstract

OBJECTIVES: This study aimed to develop further a diary originally devised to measure the impact of multiple sclerosis (MS) as part of a cost utility study of beta interferon, and to evaluate its reliability, validity, and responsiveness in an outpatient sample of people with MS.

METHODS: The original diary was further developed using qualitative and quantitative methods to ensure that it addressed the views of people with MS. The psychometric properties of the MS Symptom and Impact Diary (MSSID) were evaluated in a sample of 77 people who completed the MSSID daily for 12 weeks. Internal and test–retest reliability, discriminant and convergent validity, and responsiveness were assessed using traditional psychometric methods.

RESULTS: The MSSID formed three, internally consistent scales that measured mobility, fatigue, and the overall impact of MS. The test–retest reliability of the mobility scale was adequate for individual comparisons (ICC.0.90) and the fatigue and overall impact scales were adequate for group comparisons (ICC.0.70). The MSSID was able to distinguish between clinical groups depending on clinical course, indoor ambulation status, and relapse status. It demonstrated associations with other single point instruments in the expected direction. Compared with single point instruments, its responsiveness was similar or better, especially in detecting short term improvements in functioning.

CONCLUSIONS: The MSSID may provide a useful complement to currently available instruments to measure the outcomes of MS within clinical trials. Further research is needed to explore its feasibility in the context of a randomised controlled trial and its utility for clinicians.

Item Type: Article
Copyright, Publisher and Additional Information: © 2004 BMJ Publishing Group Ltd
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Health Sciences (Leeds)
Depositing User: Sherpa Assistant
Date Deposited: 14 Mar 2006
Last Modified: 05 Jun 2014 05:47
Published Version: http://www.jnnp.com/
Status: Published
Refereed: Yes
Identification Number: 10.1136/jnnp.2003.020529
URI: http://eprints.whiterose.ac.uk/id/eprint/247

Actions (repository staff only: login required)